共 101 条
[1]
Ansell J(2008)The pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 160S-198S
[2]
Hirsh J(2007)Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial (RE-NOVATE) Lancet 370 949-956
[3]
Hylek E(2009)Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 1673-1680
[4]
Eriksson BI(2010)Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 807-815
[5]
Dahl OE(1993)Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention Am J Med 95 315-328
[6]
Rosencher N(2010)Rivaroxaban-once daily, oral, direct factor XA inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation rationale and design of the ROCKET AF study Am Heart J 159 340-347
[7]
Turpie AGG(2005)Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin Thromb Haemost 94 537-543
[8]
Lassen MR(2007)Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 2689-2696
[9]
Davidson BL(2007)The risk of bleeding with warfarin: a systematic review and performance analysis of clinical prediction rules Thromb Haemost 98 980-987
[10]
Lassen MR(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Ann Intern Med 151 W-65-W-94